The brain-derived neurotrophic factor pathway, life stress, and chronic multi-site musculoskeletal pain

Molecular Pain

Volumn 12, Issue , 2016, Pages

  Generaal, Ellen ^a   Milaneschi, Yuri ^a   Jansen, Rick ^a   Elzinga, Bernet M ^b   Dekker, Joost ^a   Penninx, Brenda W J H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

child abuse; Chronic pain; life change events; nerve growth factors

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; ARTICLE; BDNF GENE; CHILD ABUSE; CHILDHOOD TRAUMA QUESTIONNAIRE; CROSS-SECTIONAL STUDY; DISABILITY; DISEASE SEVERITY; GENE EXPRESSION; GENOTYPE; HUMAN; LIFE STRESS; MENTAL DISEASE; MENTAL HEALTH; MIXED ANXIETY AND DEPRESSION; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; CHRONIC PAIN; FEMALE; MALE; MENTAL STRESS; METABOLISM; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC PAIN; FEMALE; HUMANS; MALE; MUSCULOSKELETAL PAIN; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 85007451749     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1177/1744806916646783     Document Type: Article

References (55)

1. Phillips K, Clauw DJ. Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum 2013; 65: 291–302.
2. Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res 2006; 55: 1–10.
3. Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci 2009; 14: 5291–5338.
4. Merighi A, Salio C, Ghirri A. BDNF as a pain modulator. Prog Neurobiol 2008; 85: 297–317.
5. Doan L, Manders T, Wang J. Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast 2015; 2015: 504691.
6. Vinberg M, Trajkovska V, Bennike B. The BDNF Val66Met polymorphism: relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Psychoneuroendocrinology 2009; 34: 1380–1389.
7. Gatt JM, Nemeroff CB, Dobson-Stone C. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009; 14: 681–695.
8. Molendijk ML, van Tol MJ, Penninx BW. BDNF val66met affects hippocampal volume and emotion-related hippocampal memory activity. Transl Psychiatry 2012; 2: e74.
9. Nijs J, Meeus M, Versijpt J. Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target? Expert Opin Ther Targets 2015; 19: 565–576.
10. Nugraha B, Korallus C, Gutenbrunner C. Serum level of brain-derived neurotrophic factor in fibromyalgia syndrome correlates with depression but not anxiety. Neurochem Int 2013; 62: 281–286.
11. Laske C, Stransky E, Eschweiler GW. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007; 41: 600–605.
12. Zanette SA, Dussan-Sarria JA, Souza A. Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol Pain 2014; 10: 46.
13. Haas L, Portela LV, Bohmer AE. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010; 35: 830–834.
14. Yu YB, Zuo XL, Zhao QJ. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012; 61: 685–694.
15. Egan MF, Kojima M, Callicott JH. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257–269.
16. Lee LC, Tu CH, Chen LF. Association of brain-derived neurotrophic factor gene Val66Met polymorphism with primary dysmenorrhea. PLoS One 2014; 9: e112766.
17. Reddy SY, Rasmussen NA, Fourie NH. Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain. BMC Med Genomics 2014; 7: 61.
18. Xiao Y, Russell IJ, Liu YG. A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein. Rheumatol Int 2012; 32: 2479–2485.
19. Anderberg UM, Marteinsdottir I, Theorell T. The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry 2000; 15: 295–301.
20. Lampe A, Doering S, Rumpold G. Chronic pain syndromes and their relation to childhood abuse and stressful life events. J Psychosom Res 2003; 54: 361–367.
21. Jones GT, Power C, Macfarlane GJ. Adverse events in childhood and chronic widespread pain in adult life: results from the 1958 British Birth Cohort Study. Pain 2009; 143: 92–96.
22. Generaal E, Vogelzangs N, Macfarlane GJ, et al. Biological stress systems, adverse life events and the onset of chronic multisite musculoskeletal pain: a 6-year cohort study. Ann Rheum Dis. Epub ahead of print 22 April 2015. DOI: 10.1136/annrheumdis-2014-206741
23. Elzinga BM, Molendijk ML, Oude Voshaar RC. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology(Berl) 2011; 214: 319–328.
24. Penninx BW, Beekman AT, Smit JH. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121–140.
25. Von Korff M, Ormel J, Keefe FJ. Grading the severity of chronic pain. Pain 1992; 50: 133–149.
26. Elliott AM, Smith BH, Smith WC. Changes in chronic pain severity over time: the Chronic Pain Grade as a valid measure. Pain 2000; 88: 303–308.
27. Smith BH, Penny KI, Purves AM. The Chronic Pain Grade questionnaire: validation and reliability in postal research. Pain 1997; 71: 141–147.
28. Von Korff M, Epidemiologic and survey methods: chronic pain assessment. In: Turk DC, Melzack R, (eds). Handbook of pain assessment, 2nd ed. New York: Guilford Press, 2001, pp. 603–618.
29. Generaal E, Vogelzangs N, Macfarlane GJ. Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders. BMC Musculoskeletal Disorders 2014; 15: 227.
30. Generaal E, Vogelzangs N, Macfarlane GJ. Basal inflammation and innate immune response in chronic multisite musculoskeletal pain. Pain 2014; 155: 1605–1612.
31. Nivard MG, Mbarek H, Hottenga JJ. Further confirmation of the association between anxiety and CTNND2: replication in humans. Genes Brain Behav 2014; 13: 195–201.
32. Boomsma DI, Willemsen G, Sullivan PF. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur J Hum Genet 2008; 16: 335–342.
33. Abecasis GR, Auton A, Brooks LD. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56–65.
34. Colzato LS, Van der Does AJ, Kouwenhoven C. BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults. Psychoneuroendocrinology 2011; 36: 1562–1569.
35. Jansen R, Batista S, Brooks AI. Sex differences in the human peripheral blood transcriptome. BMC Genomics 2014; 15: 33.
36. Wright FA, Sullivan PF, Brooks AI. Heritability and genomics of gene expression in peripheral blood. Nat Genet 2014; 46: 430–437.
37. Bus BA, Molendijk ML, Penninx BJ. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228–239.
38. de Graaf R, Bijl RV, ten Have M. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. J Affect Disord 2004; 82: 461–467.
39. Brugha T, Bebbington P, Tennant C. The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. Psychol Med 1985; 15: 189–194.
40. Abdellaoui A, Hottenga JJ, de Knijff P. Population structure, migration, and diversifying selection in the Netherlands. Eur J Hum Genet 2013; 21: 1277–1285.
41. Gerrits MM, van Marwijk HW, van Oppen P. Longitudinal association between pain, and depression and anxiety over four years. J Psychosom Res 2015; 78: 64–70.
42. Molendijk ML, Bus BA, Spinhoven P. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011; 16: 1088–1095.
43. Robins LN, Wing J, Wittchen HU. The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988; 45: 1069–1077.
44. Bus BA, Arias-Vasquez A, Franke B. Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males. Neuropsychobiology 2012; 65: 183–187. DOI:10.1159/ 000336997.
45. Molendijk ML, Bus BA, Spinhoven P. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume–a genuine effect or a winners curse? Am J Med Genet B Neuropsychiatr Genet 2012; 159B: 731–740.
46. Westra HJ, Peters MJ, Esko T. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013; 45: 1238–1243.
47. Yu H, Zhang Z, Shi Y. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J Clin Psychiatry 2008; 69: 1104–1111.
48. Fujimura H, Altar CA, Chen R. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728–734.
49. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 261–268.
50. Molendijk ML, Haffmans JP, Bus BA. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One 2012; 7: e48046.
51. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology 2012; 37: 1397–1416.
52. Naert G, Ixart G, Tapia-Arancibia L. Continuous i.c.v. infusion of brain-derived neurotrophic factor modifies hypothalamic-pituitary-adrenal axis activity, locomotor activity and body temperature rhythms in adult male rats. Neuroscience 2006; 139: 779–789.
53. Duclot F, Kabbaj M. Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. J Exp Biol 2015; 218: 21–31.
54. Wolfe F, Smythe HA, Yunus MB. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160–172.
55. Carnes D, Parsons S, Ashby D. Chronic musculoskeletal pain rarely presents in a single body site: results from a UK population study. Rheumatology (Oxford) 2007; 46: 1168–1170.